SCNI Scinai Immunotherapeutics
- 3.770
- -0.510-11.92%
Scinai Immunotherapeutics News
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Sector Update: Health Care
Top Midday Gainers
Scinai Stock Soars 54% on Preclinical Study for Psoriasis Drug
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Express News | Scinai Immunotherapeutics Shares Resume Trade
Express News | Scinai Immunotherapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 95.8%
Investors' Sentiment Rises on Trump Bets, Lifting US Equity Futures Pre-Bell
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Bet on a Trump Win
Top Premarket Gainers
Express News | Scinai Immunotherapeutics Announces In-Vivo Preclinical Study Results Of NanoAb, Says 'NanoAb Led to Reduced Levels of Both IL-17 Isoforms in the Psoriatic Skin Tissue.'
Scinai Immunotherapeutics Announces Promising Results in an In-vivo Proof-of-concept Psoriatic Human Skin Model
Scinai Immunotherapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Scinai Immunotherapeutics Eyes Debt-Equity Swap
Scinai Immunotherapeutics Strives for Nasdaq Compliance
Express News | Scinai Immunotherapeutics Receives Receipt Of Updated LoI From European Investment Bank Providing Specific Terms For Conversion Of It Loan To Equity
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent From the European Investment Bank Providing Specific Terms for Conversion of Its Loan to Equity
Express News | Scinai Immunotherapeutics Receives Nasdaq Approval To Continue Listing; Must Meet Equity Requirement By August 14, 2024
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements
Scinai Immunotherapeutics GAAP EPS of $0.00
Analysis
Price Target
No Data
